Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance-Reference-Cited by-同舟云学术

Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance

Published:2016-05-15 Issue:26 Volume:7 Page:39671-39679
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Yuan Jiajia¹,Zhang Jie²,Zhu Yan¹,Li Na³,Tian Tiantian¹,Li Yang³,Li Yanyan¹,Li Zhongwu⁴,Lai Yumei⁴,Gao Jing¹,Shen Lin¹

Affiliation:

1. Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China

2. Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China

3. Advanced Cell Diagnostics, Inc., Beijing, China

4. Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of PD-1/PD-L1 inhibitors combined with chemotherapy in patients with advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis;ONCOL LETT;2023

2. Effects of TRPV2 on the Expression of PD-L1 and Its Binding Ability to PD-1 in Gastric Cancer;Annals of Surgical Oncology;2023-08-21

3. High-Dimensional Spectral Cytometry Reveals Therapeutically Relevant Immune Subtypes in Gastric Cancer;2023-03-31

4. PD-L1 immunohistochemistry assay optimization to provide more comprehensive pathological information in classic Hodgkin lymphoma;Journal of Hematopathology;2023-02-01

5. A review of spatial profiling technologies for characterizing the tumor microenvironment in immuno-oncology;Frontiers in Immunology;2022-10-31